1. First in Wales Cellular Therapy Clinical Research Collaboration
Kay Wilson Early Phase Team Lead
Jessie Powell Senior Nurse Manager

2. UK
356,860 new cancer cases per year in UK (2014), of which 19,088 in Wales (2015)
50% survival rates 10 years or more (Eng and Wales 2011). 5 year relative survival lower than EU average
Breast, prostate, lung and bowel cancers together account for 53% of all new cancers and 46% deaths (2014)
Cancer more common in the most deprived areas - around 15,000 (5%) extra cases of cancer, per year.
19% cancer cases are caused by smoking
Larynx, lung, oral cavity and liver have over a 100% incidence gap between highest and lowest deprived areas
There are , in England, because of socio-economic variation.
In UK 46% deaths are from lung bowel Breast, prostate
Males
Cancer is more common in White and Black males than in Asian males, England
Females
Cancer is more common in White females than in Black or Asian females, England

3. WALES AND OUR REGION This is our population. These are our patients.
Most common cancers in Wales breast, prostate, lung and bowel (instances and deaths, 2013)
Melanoma biggest increase (75%+ M, 33% F)
Cancer incidence in Wales is 20% higher than in England
Parts of Wales are poorer than Romania, below EU GDP average, and slipping
19.8% of population smoke, highest rate in the UK
Incidence rate in the most deprived 22.5% higher and mortality rate in the 48% higher than in the least deprived areas in
26% of people in Wales have a limiting long-standing illness or disability - highest in UK
The highest local authority mortality rate in Blaenau Gwent is over a third higher than the lowest in neighbouring Monmouthshire in
Incidence linked to poorer society and aging population
Poverty is on the rise with 33% of children now classed as living in poverty
Cancer incidence is higher in the most deprived areas for lung cancer and colorectal cancer but the opposite pattern is true for female breast cancer and prostate cancer where the lower rates are seen in the most deprived areas.
Macro and micro – breast, prostate, bowel and lung are significant the world over
This is our population.
These are our patients.

4. The Study
An Adaptive Study of the Safety, Tolerability and Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell) in Patients with Advanced Cancers which are Refractory to Current Treatment or who have Indolent Disease for which Immunotherapy may be Beneficial.

5. Why the need to collaborate…
WE GAVE NEW ACCESS:
Cancer patients were given the opportunity to access new treatments
WE THE FIRST IN WALES:
First of it’s kind in Wales, enabling patients to receive treatment closer to home
WE ARE BUILDING THE FUTURE:
Empowering leadership in research this collaboration will give Wales the ability to continue delivering complex studies. This will benefit future generations of patients
We are a team that roll up our sleeves to get things down. We are always looking to improve services and access to patients, and give our staff opportunities, and that motivation never stops.
We didn’t feel it was fair for our patients to have to miss out on new and innovative treatments because of where they lived, the disease or where they were treated. Sometimes these trials are the only chance that people (like Alan here) have to see their children marry and their grandchildren grow. We wanted to increase access to patients and their families who all deserve a chance.
There was nothing in Wales available – if patients wanted to be on the trial they would have had to have travelled at least 2 further hours down the M4 to seek treatment. Our patients are ill and deserve time with their loved ones rather than doing 8 hour round trips when they are feeling poorly. We wanted out patients to have something on their doorstep.
We are a senior leadership team with big aspirations and a shared vision. We want our staff to be enabled to do things rather than stick with the norm or not feel empowered to make positive change. We take the responsibility of leadership and staff growth seriously. We had to jump through lots of hoops to get the trial running, as we couldn’t have delivered this trial without our collaboration - but we did it – and the precedent and example has been set – this collaboration will be the first of many.

6. Clinical Effectiveness
The detail…
Innovation
Patient Value
Patient Focus
Collaboration
Clinical Effectiveness
Leadership
Adaptability
Sustainability

7. FOCUSED PARTNERSHIP CANCER RESEARCH
GLOBAL IMPACT
FOCUSED PARTNERSHIP CANCER RESEARCH
Expertise
Partners
Patients
Meeting local demand responds to national and global – we will all benefit
lets us drive local research that can drive our international reputation

8. World Class Research

9. Thank you
Any Questions?